Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities
Por:
Pascual J, Diekmann F, Fernández-Rivera C, Gómez-Marqués G, Gutiérrez-Dalmau A, Pérez-Sáez MJ, Sancho-Calabuig A and Oppenheimer F
Publicada:
1 may 2017
Ahead of Print:
24 may 2017
Categoría:
Nephrology
Resumen:
The immunosuppressive combination most commonly used in de novo kidney transplantation comprises a calcineurin inhibitor (CI), tacrolimus, a mycophenolic acid derivative and steroids. The evidence which underlies this practice is based in the Symphony trial with controlled follow-up of one year, in which no comparator group included the combination CI-mTOR inhibitor. Different high-quality clinical trials support the use of everolimus as a standard immunosuppressive drug associated with reduced exposure of a CI in kidney transplantation. This combination could improve health related outcomes in kidney transplantation recipients.
The present recommendations constitute an attempt to summarise the scientific evidence supporting this practice, discuss false beliefs, myths and facts, and offer specific guidelines for safe use, avoiding complications. (C) 2016 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U.
Filiaciones:
Pascual J:
Servicio de Nefrología, Hospital del Mar, Barcelona, España.
Diekmann F:
Servicio de Nefrología, Hospital Clìnic, Barcelona, España
Fernández-Rivera C:
Servicio de Nefrología, Complexo Hospitalario Universitario A Coruña, La Coruña, España
Gómez-Marqués G:
Servicio de Nefrología, Hospital Son Espasses, Palma de Mallorca, España
Gutiérrez-Dalmau A:
Servicio de Nefrología, Hospital Miguel Servet, Zaragoza, España
Pérez-Sáez MJ:
Servicio de Nefrología, Hospital del Mar, Barcelona, España
:
Servicio de Nefrología, Hospital Doctor Peset, Valencia, España
Oppenheimer F:
Servicio de Nefrología, Hospital Clìnic, Barcelona, España
Green Accepted, gold
|